Royal Bank of Canada Lowers Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $8.00

Inovio Pharmaceuticals (NASDAQ:INO) had its price objective cut by Royal Bank of Canada from $11.00 to $8.00 in a research report report published on Friday, Benzinga reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. HC Wainwright reissued a neutral rating and set a $15.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, July 15th. Stephens began coverage on Inovio Pharmaceuticals in a research note on Tuesday, May 14th. They issued an overweight rating and a $20.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and an average target price of $44.00.

Inovio Pharmaceuticals Trading Down 1.4 %

INO stock opened at $8.32 on Friday. The firm has a market cap of $215.58 million, a PE ratio of -2.59 and a beta of 0.89. The stock has a 50-day moving average price of $9.45 and a 200-day moving average price of $9.81. Inovio Pharmaceuticals has a 1-year low of $3.89 and a 1-year high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.09). Inovio Pharmaceuticals had a negative return on equity of 88.13% and a negative net margin of 16,238.91%. The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. During the same quarter in the previous year, the firm posted ($1.56) earnings per share. On average, analysts forecast that Inovio Pharmaceuticals will post -4.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Susquehanna Fundamental Investments LLC bought a new stake in Inovio Pharmaceuticals during the first quarter worth $1,482,000. Vanguard Personalized Indexing Management LLC grew its stake in shares of Inovio Pharmaceuticals by 5.6% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 115,361 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 6,148 shares in the last quarter. Keystone Financial Group raised its holdings in shares of Inovio Pharmaceuticals by 11.7% in the fourth quarter. Keystone Financial Group now owns 122,737 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 12,840 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter valued at about $605,000. Finally, American Century Companies Inc. lifted its position in shares of Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 12,100 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.